午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

ChemicalBook--->CAS DataBase List--->2244440-85-3

2244440-85-3

2244440-85-3 Structure

2244440-85-3 Structure
IdentificationBack Directory
[Name]

Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans-
[CAS]

2244440-85-3
[Synonyms]

omesdafexor
Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans-
[Molecular Formula]

C34H43N3O3
[MOL File]

2244440-85-3.mol
[Molecular Weight]

541.72
Chemical PropertiesBack Directory
[Boiling point ]

735.5±60.0 °C(Predicted)
[density ]

1.24±0.1 g/cm3(Predicted)
[form ]

Solid
[pka]

14.96±0.40(Predicted)
[color ]

White to off-white
Hazard InformationBack Directory
[Uses]

Omesdafexor (MET642) is an oral FXR agonist. Omesdafexor can improve colitis induced by adoptive T cell transfer,promote intestinal antimicrobial function, barrier function and inhibit inflammation [1][2][3].
[in vivo]

Omesdafexor (0.03-0.3 mg/kg, orally, once daily, four weeks) with tofacitinib can synergistically improve colitis[2].
Omesdafexor (0.1-1 mg/kg, orally, once daily, four weeks) can improve colitis induced by adoptive T cell transfer[3].

Animal Model:Colitis mouse model [2]
Dosage:0.03, 0.3 mg/kg; once a day; four weeks
Administration:Oral
Result:Reduced the number of innate immune cells in mesenteric lymph nodes, but not T cells, and could synergistically improve colitis when used in combination with tofacitinib.
Animal Model:Transplanting CD4+CD45RBhi T-cells to recipient C.B-17 SCID mice[3]
Dosage:0.1, 0.3, 1 mg/kg; once a day; four weeks
Administration:Oral
Result:Improved adoptive T cell transfer-induced colitis, promoted intestinal antimicrobial function, barrier function and inhibited inflammation.
[References]

[1] https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf?sfvrsn=8544ca1e_3&download=true
[2] Xueqing Liu, et al. COMBINATION OF FXR AGONIST MET642 WITH TOFACITINIB EXHIBITS SYNERGISTIC EFFECTS IN IMPROVING COLITIS IN ADOPTIVE T-CELL TRANSFER IBD MODEL. METACRINE.
[3] Xueqing Liu, et al. P153 MET642, AN ORAL FXR AGONIST, IMPROVES COLITIS INDUCED BY ADOPTIVE T-CELL TRANSFER. Volume 158, Issue 3, Supplement S11February 2020.
2244440-85-3 suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Website: https://www.targetmol.cn/
Tags:2244440-85-3 Related Product Information

  • HomePage | Member Companies | Advertising | Contact us | Previous WebSite | MSDS | CAS Index | CAS DataBase | Privacy | Terms | About Us
  • All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
    According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.
  • Copyright © 2023 ChemicalBook All rights reserved.